This is an application for continuation of a 10 year old project whose goal is to understand the regulation and function of different signaling responses controlled by the I?B kinase (IKK) complex and its three subunits: IKKa, IKK?, and IKK?. Progress during the previous project period has been considerable - in addition to improved understanding of IKK regulation and its role in NF-?B activation, we have elucidated the roles of the two IKK catalytic subunits (IKKa and IKK?) in the control of innate immunity and inflammation as well as programmed cell death, cancer, chronic inflammatory disorders and autoimmunity. During the course of these studies, we made several unanticipated and rather surprising findings that we plan to pursue in greater detail during the next project period. These findings include the identification of the Hif1a gene, which encodes the hypoxia regulated HIF-1a subunit of the HIF-1 transcription factor, as an IKK and NF-?B regulated gene. These results suggest that in addition to its key role in suppression of apoptosis and activation of host defense and inflammation, NF-?B is also a critical regulator of the hypoxic response. In addition to studying the regulation of IKK? activity by hypoxia we will conduct studies that should clarify the pathophysiological importance of these findings in the control of innate immunity and tumor-elicited inflammation. Another unanticipated finding is the involvement of IKK?(NEMO), the IKK regulatory subunit, in activation of the JNK and p38 MAPK pathways in B cells stimulated via CD40 or BAFF receptor (BAFF-R). We will study the mechanism by which IKK? controls the activation of these pathways through formation of a signaling complex that includes TRAF2 and MEKK1, which are E3 ubiquitin ligases, and UBC13, an E2 ubiquitin conjugating enzyme. In addition we will continue to study the role of TRAF2 and its relative TRAF3 in controlling the activation of the IKK-dependent alternative NF-?B signaling pathway in response to engagement of CD40, RANK, BAFF-R and lymphotoxin(LT) a:? receptor (LT?R). We will focus on the role of TRAF2 and TRAF3 in controlling the turnover of NIK, a protein kinase responsible for IKKa activation. A third unexpected finding that will be followed up on is a role for activated nuclear IKKa in transcriptional regulation that is not related to its already known functions in regulation of the classical and alternative NF-?B signaling pathways. Although we first found this novel function of nuclear IKK in prostate cancer we will study its relevance to signaling by IKKa-activating receptors in cell types present within secondary lymphoid organs, such as the spleen, whose development and function are IKKa-dependent. As before, these studies will advance both our basic understanding of IKK signaling as well as its varied and wide-reaching pathophysiological functions. Project Narrative: This is an application for continuation of a 10 year old project focused on the regulation and function of the I?B kinase (IKK) complex, a master regulator of immunity, host defense and cell survival. The new studies will follow unexpected findings made during the previous project period that pertain to roles of IKK subunits in control of the hypoxic response during microbial infections and tumor-elicited inflammation and regulation of the alternative NF-?B signaling pathway, which is important for lymphoid organ development and function, as well as the pathogenesis of autoimmunity. Other new findings that will be studied in further detail are the role of the IKK? subunit in signaling to MAPK cascades during activation of antibody-producing B cells and novel nuclear functions for IKKa in cells of secondary lymphoid organs, which are important players in immunity and inflammatory diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043477-15
Application #
8206660
Study Section
Cellular and Molecular Immunology - A Study Section (CMIA)
Program Officer
Mallia, Conrad M
Project Start
1998-07-01
Project End
2013-06-23
Budget Start
2012-01-01
Budget End
2013-06-23
Support Year
15
Fiscal Year
2012
Total Cost
$467,908
Indirect Cost
$165,055
Name
University of California San Diego
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Wu, Xuefeng; Zhang, Weizhou; Font-Burgada, Joan et al. (2014) Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci U S A 111:13870-5
Sun, Beicheng; Karin, Michael (2014) The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci 35:349-57
Valeri, Nicola; Braconi, Chiara; Gasparini, Pierluigi et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25:469-83
Charlaftis, Nikolaos; Suddason, Tesha; Wu, Xuefeng et al. (2014) The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines. EMBO J 33:2581-96
Wang, Kepeng; Kim, Min Kyoung; Di Caro, Giuseppe et al. (2014) Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41:1052-63
Li, Ning; Wu, Xuefeng; Holzer, Ryan G et al. (2013) Loss of acinar cell IKK* triggers spontaneous pancreatitis in mice. J Clin Invest 123:2231-43
Gukovsky, Ilya; Li, Ning; Todoric, Jelena et al. (2013) Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 144:1199-209.e4
Mancino, Alessandra; Habbeddine, Mohamed; Johnson, Ella et al. (2013) I kappa B kinase alpha (IKKýý) activity is required for functional maturation of dendritic cells and acquired immunity to infection. EMBO J 32:816-28
Li, Ning; Grivennikov, Sergei I; Karin, Michael (2011) The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19:429-31
Hacker, Hans; Tseng, Ping-Hui; Karin, Michael (2011) Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 11:457-68

Showing the most recent 10 out of 65 publications